硼替佐米联合R—EPOCH方案在老年复发或难治套细胞淋巴瘤中的临床观察(3)
[3]范磊,徐卫,李建勇.2014版中国B细胞慢性淋巴增殖性疾病诊断专家共识解读[J].临床血液学杂志,2014,27(11):941-943.
[4] Howard O M,Gribben J G,Neuberg D S,et al.Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma:molecular complete responses are not predictive of progression-free survival[J].J Clin Oncol,2002,20(5):1288-1294.
[5]聂蔓,李志铭,魏小娟,等.基于硼替佐米的治疗方案在老年初治套细胞淋巴瘤中的应用[J].循证医学,2016,16(2):83-85.
[6]朱米娜,白庆咸,杨岚,等.16例套细胞淋巴瘤临床病例分析[J].临床血液学杂志,2014,27(7):593-596.
[7]陈玉清,周东,时杰,等.硼替佐米治疗难治复发非霍奇金淋巴瘤的临床观察[J].临床医学,2012,32(6):9-11.
[8]彭太芳.套细胞淋巴瘤诊治及预后研究进展[J].现代医药卫生,2015,31(24):3738-3741.
[9] Koprivnikar J L,Cheson B D.Bortezomib:a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin' s lymphoma[J].Future Oncol,2012,8(4):359-371.
[10] Bose P,Batalo M S,Holkova B.Bortezomib for the treatment of non-Hodgkin’s lymphoma [J].Expert Opin Pharmacother,2014,15(16):2443-2459.
[11] Hutter G,Rieken M,Pastore A.The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in asequence-dependent way with chemotherapeutic agents in mantle cell lymphoma[J].Ann Hematol,2012,91(6):847-856.
[12] Kouroukis T C,Baldassarre F G,Haynes A E.Bortezomib in multiple myeloma:systematic review and clinical considerations[J].Curr Oncol,2014,21(4):573-603.
[13]葛杭萍,蔡芳芳,俞康.硼替佐米联合EPOCH治疗复发难治性非霍奇金淋巴瘤[J].醫学研究杂志,2014,43(2):50-54.
(收稿日期:2017-04-20), http://www.100md.com(周倩)
[4] Howard O M,Gribben J G,Neuberg D S,et al.Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma:molecular complete responses are not predictive of progression-free survival[J].J Clin Oncol,2002,20(5):1288-1294.
[5]聂蔓,李志铭,魏小娟,等.基于硼替佐米的治疗方案在老年初治套细胞淋巴瘤中的应用[J].循证医学,2016,16(2):83-85.
[6]朱米娜,白庆咸,杨岚,等.16例套细胞淋巴瘤临床病例分析[J].临床血液学杂志,2014,27(7):593-596.
[7]陈玉清,周东,时杰,等.硼替佐米治疗难治复发非霍奇金淋巴瘤的临床观察[J].临床医学,2012,32(6):9-11.
[8]彭太芳.套细胞淋巴瘤诊治及预后研究进展[J].现代医药卫生,2015,31(24):3738-3741.
[9] Koprivnikar J L,Cheson B D.Bortezomib:a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin' s lymphoma[J].Future Oncol,2012,8(4):359-371.
[10] Bose P,Batalo M S,Holkova B.Bortezomib for the treatment of non-Hodgkin’s lymphoma [J].Expert Opin Pharmacother,2014,15(16):2443-2459.
[11] Hutter G,Rieken M,Pastore A.The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in asequence-dependent way with chemotherapeutic agents in mantle cell lymphoma[J].Ann Hematol,2012,91(6):847-856.
[12] Kouroukis T C,Baldassarre F G,Haynes A E.Bortezomib in multiple myeloma:systematic review and clinical considerations[J].Curr Oncol,2014,21(4):573-603.
[13]葛杭萍,蔡芳芳,俞康.硼替佐米联合EPOCH治疗复发难治性非霍奇金淋巴瘤[J].醫学研究杂志,2014,43(2):50-54.
(收稿日期:2017-04-20), http://www.100md.com(周倩)